---
schema_version: "secwatch.filing_event.v1"
accession: "0001645113-25-000009"
form_type: "8-K"
ticker: "NVCR"
cik: "0001645113"
company_name: "NovoCure Ltd"
filed_at: "2025-04-24T23:59:59+00:00"
generated_at: "2026-05-23T07:04:27.817180+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Novocure Q1 revenue $155M (+12% YoY), net loss $34.3M; CE Mark for Optune Lua NSCLC

## Summary
- Revenue $155M, +12% YoY; net loss $34.3M ($0.31 loss per share); adj. EBITDA -$5.0M; cash $929M.
- Active patients 4,268; Optune Gio active patients +9% to 4,162; Optune Lua patients 106 (62 NSCLC, 44 MPM).
- CE Mark approved for Optune Lua with immune checkpoint inhibitors or docetaxel in metastatic NSCLC after platinum progression.
- Tariff risk: up to $11M if tariffs resume post-90-day pause; up to $8M if pause extended; monitoring mitigation.
- PANOVA-3 Phase 3 pancreatic cancer results accepted as late-breaking abstract at ASCO 2025; milestones H1 2026.

## SEC filing metadata
- accession: 0001645113-25-000009
- form_type: 8-K
- ticker: NVCR
- cik: 0001645113
- company_name: NovoCure Ltd
- filed_at: 2025-04-24T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645113/000164511325000009/0001645113-25-000009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645113/000164511325000009/nvcr-20250424.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001645113-25-000009
- JSON: https://secwatch.observer/filing/0001645113-25-000009.json
- Plain text: https://secwatch.observer/filing/0001645113-25-000009.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.